We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Anti-phospholipid human monoclonal antibodies inhibit CCR5-tropic HIV-1 and induce beta-chemokines.
- Authors
Moody, M Anthony; Liao, Hua-Xin; Alam, S Munir; Scearce, Richard M; Plonk, M Kelly; Kozink, Daniel M; Drinker, Mark S; Zhang, Ruijun; Xia, Shi-Mao; Sutherland, Laura L; Tomaras, Georgia D; Giles, Ian P; Kappes, John C; Ochsenbauer-Jambor, Christina; Edmonds, Tara G; Soares, Melina; Barbero, Gustavo; Forthal, Donald N; Landucci, Gary; Chang, Connie; King, Steven W; Kavlie, Anita; Denny, Thomas N; Hwang, Kwan-Ki; Chen, Pojen P; Thorpe, Philip E; Montefiori, David C; Haynes, Barton F
- Abstract
Traditional antibody-mediated neutralization of HIV-1 infection is thought to result from the binding of antibodies to virions, thus preventing virus entry. However, antibodies that broadly neutralize HIV-1 are rare and are not induced by current vaccines. We report that four human anti-phospholipid monoclonal antibodies (mAbs) (PGN632, P1, IS4, and CL1) inhibit HIV-1 CCR5-tropic (R5) primary isolate infection of peripheral blood mononuclear cells (PBMCs) with 80% inhibitory concentrations of <0.02 to approximately 10 microg/ml. Anti-phospholipid mAbs inhibited PBMC HIV-1 infection in vitro by mechanisms involving binding to monocytes and triggering the release of MIP-1alpha and MIP-1beta. The release of these beta-chemokines explains both the specificity for R5 HIV-1 and the activity of these mAbs in PBMC cultures containing both primary lymphocytes and monocytes.
- Publication
The Journal of experimental medicine, 2010, Vol 207, Issue 4, p763
- ISSN
1540-9538
- Publication type
Journal Article
- DOI
10.1084/jem.20091281